SCHEMBL103727

SCHEMBL103727

Nc1nc2c(Cl)cccc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 1.00
PDE10A Q9Y233 1/20 1.00
ALDH1A1 P00352 4/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
PDPK1 O15530 1/20 0.61
HPGD P15428 3/20 0.61
MAPT P10636 3/20 0.61
TDP1 Q9NUW8 2/20 0.61
GAA P10253 2/20 0.61
KMT2A Q03164 2/20 0.61
MAPK1 P28482 2/20 0.61
MEN1 O00255 1/20 0.61
PKM P14618 1/20 0.61
PSMB8 P28062 1/20 0.56
CYP3A4 P08684 1/20 0.56
RAB9A P51151 1/20 0.50
NPC1 O15118 1/20 0.46
HSD17B10 Q99714 2/20 0.43
KDM4E B2RXH2 1/20 0.42
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2002578 0.98 LMNA (0.96) LMNAPDE10AALDH1A1SMN1; SMN2PDPK1
Sulfuric Acid SCHEMBL9010159 0.90 LMNA (0.81) LMNAPDE10AALDH1A1SMN1; SMN2PDPK1
SCHEMBL6707554 0.84 LMNA (0.71) LMNAPDE10AALDH1A1SMN1; SMN2PDPK1
SCHEMBL8128010 0.84 LMNA (0.71) LMNAPDE10AALDH1A1SMN1; SMN2PDPK1
SCHEMBL969167 0.79 ALDH1A1 (0.66) LMNAPDE10AALDH1A1SMN1; SMN2PDPK1
SCHEMBL1747928 0.79 LMNA (0.66) LMNAPDE10AALDH1A1SMN1; SMN2HPGD
SCHEMBL2433144 0.78 LMNA (0.63) LMNAPDE10AALDH1A1SMN1; SMN2HPGD
Hydrochloric Acid SCHEMBL28787382 0.78 ALDH1A1 (0.63) LMNAPDE10AALDH1A1SMN1; SMN2PDPK1
SCHEMBL24858578 0.76 ALDH1A1 (0.61) LMNAPDE10AALDH1A1SMN1; SMN2PDPK1
SCHEMBL21395484 0.76 LMNA (0.61) LMNAPDE10AALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119775273-A Riluzole/ciprofloxacin heterozygote and derivative thereof, and preparation method and application thereof 赣南医科大学第一附属医院 2025-04-08 CN claimed
CN-113045993-A Polishing solution for processing ultra-smooth low-damage bearing steel surface and application thereof 西南交通大学 2021-06-29 CN claimed
CN-110964366-A Carbon-series conductive filler in water-based conductive electrostatic coating and preparation method thereof 哈尔滨奥晶云科技有限公司 2020-04-07 CN claimed
CN-106749097-B A kind of chloro- 2- aminobenzothiazole analog derivative of 6- and its preparation method and application 温州医科大学 2019-07-16 CN claimed
CN-107417705-B Imidazo [2,1-b] benzothiazole compound and its synthetic method 湘潭大学 2019-07-02 CN claimed
CN-107973807-A Triazolobenzothiazole derivative and preparation method and application thereof 唐山学院 2018-05-01 CN claimed
CN-107417705-A Imidazo [2,1 b] benzothiazole compound and its synthetic method 湘潭大学 2017-12-01 CN claimed
CN-106749097-A A kind of aminobenzothiazole analog derivative of 6 chlorine 2 and its preparation method and application 温州医科大学 2017-05-31 CN claimed
US-9255182-B2 Data storage medium and method for high density data storage INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2016-02-09 US claimed
CN-104231659-A Red thiazole heterocyclic disperse dye compound containing benzoate group and preparation and application thereof YU XINGYING 2014-12-24 CN claimed
WO-2002053156-A1 METHOD FOR TREATING GLAUCOMA II B ALTEON, INC. (US) 2002-07-11 WO claimed
US-20020022622-A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging SYNVISTA THERAPEUTICS, INC. 2002-02-21 US claimed
WO-2001052847-A1 THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING ALTEON, INC. (US) 2001-07-26 WO claimed
US-5594145-A Process for the preparation of 2(3H)-benzothiazolones HOECHST AG (DE) 1997-01-14 US claimed
EP-0282971-B1 Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents WARNER LAMBERT CO (US) 1994-12-28 EP claimed
EP-0622362-A1 Process for the preparation of 2(3H) benzolthiazolons HOECHST AKTIENGESELLSCHAFT (DE) 1994-11-02 EP claimed
EP-0331052-A2 Process for the preparation of imidized acrylic polymers ELF ATOCHEM ITALIA S.r.l. (IT) 1989-09-06 EP claimed
US-4826860-A STROKES WARNER-LAMBERT COMPANY (US) 1989-05-02 US claimed
EP-0282971-A2 Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents WARNER-LAMBERT COMPANY (US) 1988-09-21 EP claimed
US-3937714-A 2-AMINOBENZOTHIAZOLES, HYDRAZINE, ACID CATALYSTS ELI LILLY AND COMPANY (US) 1976-02-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022622-A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging ABAT, NDUFAB1, HSPE1 LMNA 2059/4885PDE10A 2664/4885ALDH1A1 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.